NCT06004986View on ClinicalTrials.gov

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

PHASE4RecruitingINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

August 14, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

December 31, 2025

Conditions
Atopic DermatitisAtopic Dermatitis Eczema
Interventions
DRUG

Dupilumab

Administering Dupilumab 300 mg at different dosing intervals.

Trial Locations (2)

1105 AZ

RECRUITING

Amsterdam University Medical Centers, Amsterdam

3015 GD

NOT_YET_RECRUITING

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

Prothya Biosolutions

INDUSTRY

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER